Hasmukh Chudgar & family (#496)
- $ 8 B
- Pharmaceuticals
- India
- M
- 92 Years
'A form of double taxation': Are management fees on new houses quietly getting out of control?
Trump Official Blames Biden Admin for Economic ‘Mess’ — As Resurfaced Clip Shows Him Saying Trump Would Own the Economy By 2026
Is Precigen, Inc. (PGEN) A Good Stock To Buy Now?
Is Transocean Ltd. (RIG) A Good Stock To Buy Now?
Tesla is selling Chinese-made cars in Canada to escape the tariffs that both China and America imposed on it
Insecurity didn’t start with Tinubu, group defends president’s security record
Vibrating pillow sleeve warns deaf sleepers of burglars and fires
How Kepler built verifiable AI for financial services with Claude
Is ASML Holding N.V. (ASML) A Good Stock To Buy Now?
5-Letter Words Ending in ‘Y’ to Help You Improve Your Wordle Skills
About Me
Low profile Hasmukh Chudgar founded generics maker Intas Pharmaceuticals in 1977. Chudgar has long handed over operations to his sons Nimish and Binish, who run the $3.5 billion (revenue) company. In August 2025, Intas Pharma acquired biosimilar company Udenyca from California-based Coherus Life Sciences for $558 million. The company's portfolio includes an affordable drug to treat breast cancer called Eleftha, which is similar to Roche's Herceptin. In 2022, the Abu Dhabi Investment Authority bought a 3% stake in Intas from Temasek.
Achievements
Career Highlights
A snapshot of the defining milestones, leadership decisions, and breakthroughs that shaped Hasmukh Chudgar & family’s rise and global influence.
Wealth Growth
Net Worth Growth Over Time
Tracking Hasmukh Chudgar & family’s net worth journey over the years, highlighting key growth phases and financial milestones.
Current Net Worth: $7.6B
(April 29, 2026)
© Iconic Billionaires